文献速递生殖医学

生育药物与丹麦全国146024例不孕女性队列中甲状腺癌发病率的关系

Fertility drugs and incidence of thyroid cancer in a Danish nationwide cohort of 146 024 infertile women.
PubMed 文献 · Hum Reprod · 2022-01-01

该回顾性全国队列纳入丹麦1995-2017年146024例20-45岁不孕女性,随访至2018年12月31日,中位随访11.3年,167例发生甲状腺癌。多数生育药物使用与甲状腺癌风险无关,但曾用孕激素与总体及乳头状甲状腺癌风险升高相关(HR 1.63和1.66),作者认为不能排除偶然发现,需进一步研究。

要点

  • 多数生育药物(枸橼酸氯米芬、hCG、促性腺激素、GnRH受体调节剂)使用与甲状腺癌风险无显著关联。
  • 曾用孕激素与总体甲状腺癌风险升高相关(HR 1.63;95%CI 1.07-2.48)。
  • 曾用孕激素与乳头状甲状腺癌风险升高相关(HR 1.66;95%CI 1.04-2.65)。

核心结论

  • 多数类型生育药物使用与甲状腺癌风险升高无关。
  • 曾用孕激素与总体及乳头状甲状腺癌发病率升高相关,但作者认为不能排除偶然发现,需在大型流行病学研究中进一步研究。

研究设计与样本

  • 回顾性、基于人群的队列研究,纳入1995-2017年丹麦所有146024例20-45岁不孕女性。
  • 从首次不孕诊断日期随访至甲状腺癌或其他癌症(除外非黑色素瘤皮肤癌)、死亡、移民、全甲状腺切除术或随访结束(2018年12月31日),以先发生者为准。
  • 中位随访时间11.3年,随访期间167例女性诊断为甲状腺癌。
  • 采用Cox比例风险回归模型计算总体甲状腺癌及乳头状甲状腺癌的风险比(HR)和95%CI。

主要发现

  • 调整不孕诊断日历年、最高教育水平、产次状态、肥胖或甲状腺疾病及对其他登记生育药物的相互调整后,枸橼酸氯米芬、hCG、促性腺激素或GnRH受体调节剂使用与总体或乳头状甲状腺癌风险无显著关联。
  • 对其他特定生育药物相互调整后,曾用孕激素与总体甲状腺癌风险升高相关(HR 1.63;95%CI 1.07-2.48)。
  • 对其他特定生育药物相互调整后,曾用孕激素与乳头状甲状腺癌风险升高相关(HR 1.66;95%CI 1.04-2.65)。
  • 对多数特定生育药物,开始用药后5年内与甲状腺癌的关联倾向于高于开始用药5年后。
  • 未发现任何特定生育药物累积剂量与甲状腺癌风险存在显著关联。

临床怎么用

  • 作者认为该研究结果为参与不孕症诊断和治疗的临床医生及其他卫生保健人员提供了有价值的知识。
  • 作者认为孕激素使用与甲状腺癌之间的潜在关联应在大型流行病学研究中进一步研究。

局限性

  • 尽管研究人群较大,但部分亚组分析因甲状腺癌病例数少,统计精度可能受影响。
  • 虽然调整了多个潜在混杂因素,但残留和未测量混杂可能影响观察到的关联,因无法调整可能影响生育药物与甲状腺癌关联的某些因素,包括月经初潮年龄和BMI。
  • 作者不能排除孕激素与甲状腺癌的关联为偶然发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do fertility drugs increase the risk of thyroid cancer among infertile women? SUMMARY ANSWER: The use of most types of fertility drugs was not associated with an increased risk of thyroid cancer. WHAT IS KNOWN ALREADY: The incidence of thyroid cancer is higher for women than men, especially during reproductive years, indicating that reproductive hormones may be involved in the development of thyroid cancer. Only a few previous studies have examined the association between the use of fertility drugs and incidence of thyroid cancer and the results are inconclusive. STUDY DESIGN, SIZE, DURATION: A retrospective, population-based cohort study including all 146 024 infertile women aged 20-45 years and living in Denmark in the period 1995-2017. The women were followed from the date of entry in the cohort (i.e. date of first infertility diagnosis) until the occurrence of thyroid cancer or any other cancer (except non-melanoma skin cancer), death, emigration, total thyroidectomy or the end of follow-up (31 December 2018), whichever occurred first. The median length of follow-up was 11.3 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 167 women were diagnosed with thyroid cancer during the follow-up period. Information on the use of specific fertility drugs (clomiphene citrate, gonadotropins, hCGs, GnRH receptor modulators and progesterone), thyroid cancer, covariates and vital status was obtained from the Danish Infertility Cohort and various Danish national registers. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% CIs for thyroid cancer overall and for papillary thyroid cancer. MAIN RESULTS AND THE ROLE OF CHANCE: After adjustment for the calendar year of infertility diagnosis, the highest obtained level of education, parity status, obesity or thyroid disease and mutual adjustment for other registered fertility drugs, no marked associations were observed between the use of clomiphene citrate, hCG, gonadotropins or GnRH receptor modulators and risk of overall or papillary thyroid cancer. However, ever use of progesterone was associated with an increased rate of both overall (HR 1.63; 95% CI 1.07-2.48) and papillary (HR 1.66, 95% CI 1.04-2.65) thyroid cancer after mutual adjustment for other specific fertility drugs. For most specific fertility drugs, we observed a tendency toward higher associations with thyroid cancer within the first 5 years after the start of drug use than after 5 years from the start of use. No marked associations were detected according to the cumulative dose for any of the specific fertility drugs. LIMITATIONS, REASONS FOR CAUTION: Despite a large study population, the statistical precision in some subgroup analyses may be affected due to the low number of thyroid cancer cases. Although we were able to adjust for a number of potential confounders, residual and unmeasured confounding may potentially have affected the observed associations, as we could not adjust for some factors that may influence the association between fertility drugs and thyroid cancer, including age at menarche and BMI. WIDER IMPLICATIONS OF THE FINDINGS: Although this study, which is the largest to date, provides reassuring evidence that there is no strong link between the use of fertility drugs and thyroid cancer incidence, we observed a modest increased thyroid cancer incidence after the use of progesterone. However, we cannot rule out that this is a chance finding and the potential association between the use of progesterone and thyroid cancer should therefore be investigated further in large epidemiological studies. The results of the present study provide valuable knowledge for clinicians and other health care personnel involved in the diagnosis and treatment of infertility. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by research grants from the Jascha Foundation and the Aase and Ejner Danielsens Foundation. B.N. received honoraria and/or non-financial support by Gedeon Richter Nordics AB, IBSA Nordic APS and Merck KGAA. The remaining authors have no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lindquist S, Kjær SK, Albieri V, et al. Fertility drugs and incidence of thyroid cancer in a Danish nationwide cohort of 146 024 infertile women. Hum Reprod. 2022. PMID: 35020884. doi:10.1093/humrep/deab285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。